Vertex Pharmaceuticals
VRTX
431 hedge funds and large institutions have $26.2B invested in Vertex Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 161 increasing their positions, 140 reducing their positions, and 41 closing their positions.
59% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 41
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
21% more capital invested
Capital invested by funds: $21.7B → $26.2B (+$4.58B)
15% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 140
5% more funds holding
Funds holding: 411 → 431 (+20)
1.03% more ownership
Funds ownership: 96.12% → 97.15% (+1%)
0% more call options, than puts
Call options by funds: $567M | Put options by funds: $566M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$323M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$230M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$102M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$95.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$94.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$288M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$147M |
| 3 |
Jennison Associates
New York
|
-$135M |
| 4 |
Goldman Sachs
New York
|
-$74.8M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$71.4M |
VRTX Hedge Fund Activity: Q3 2014 in Review
431 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2014, worth a combined $26.2B — up 21% from $21.7B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new VRTX positions and 41 closed out — a net gain of 24 holders — while 161 added to existing stakes and 140 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $323M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $288M sold.
- 431 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2014, up from 411 in Q2 2014.
- Funds reported $26.2B of Vertex Pharmaceuticals stock for Q3 2014, up 21% quarter-over-quarter.
- 65 funds opened new Vertex Pharmaceuticals positions in Q3 2014 and 41 closed out, a net change of +24 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2014 was Wellington Management Group, an estimated $323M added.
- The largest Vertex Pharmaceuticals seller in Q3 2014 was Loomis, Sayles & Company, an estimated $288M sold.
Based on aggregated 13F filings for Q3 2014.